Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Dongying Liao"'
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 5, Pp n/a-n/a (2024)
Abstract Background Lung adenocarcinoma (LUAD) is one of the most invasive malignant tumor of the respiratory system. It is also the common pathological type leading to the death of LUAD. Maintaining the homeostasis of immune cells is an important wa
Externí odkaz:
https://doaj.org/article/1cbd95c345824ccc89066a23b236f31f
Autor:
Yidan Sun, Yixun Chen, Xin Zhang, Dan Yi, Fanming Kong, Linlin Zhao, Dongying Liao, Lei Chen, Qianqian Ma, Ziheng Wang
Publikováno v:
Heliyon, Vol 10, Iss 7, Pp e28162- (2024)
Brain metastasis (BMs) in small cell lung cancer (SCLC) has a very poor prognosis. This study combined WGCNA with the mfuzz algorithm to identify potential biomarkers in the peripheral blood of patients with BMs. By comparing the significantly differ
Externí odkaz:
https://doaj.org/article/3b223503e73e4ebbb393d9c81610295b
Autor:
Lu Zhao, Qingyun Mei, Yongchao Yu, Na Wang, Dou Zhang, Dongying Liao, Jinhui Zuo, Hongxia Xie, Yingjie Jia, Fanming Kong
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and sel
Externí odkaz:
https://doaj.org/article/fbb5bb44e3a843f3b954d28feb790fe3
Autor:
Na Wang, Qingyun Mei, Ziwei Wang, Lu Zhao, Dou Zhang, Dongying Liao, Jinhui Zuo, Hongxia Xie, Yingjie Jia, Fanming Kong
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Gastric cancer is an intractable malignant tumor that has the fifth highest morbidity and the third highest mortality in the world. Even though various treatment options did much to ameliorate the prognosis of advanced gastric cancer, the survival ti
Externí odkaz:
https://doaj.org/article/8fc210ecb64e44a39f0937a3e1451cd7
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Lung cancer is the leading cause of cancer deaths in the world. At present, immunotherapy has made a great breakthrough in lung cancer treatment. A variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies
Externí odkaz:
https://doaj.org/article/8b41b319fbc447fda91a0366fb29e4ce
Publikováno v:
Breast Cancer: Targets and Therapy. 15:281-294
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faa259d617a3ecfc5fef8130a72848e5
https://doi.org/10.2147/bctt.s407181
https://doi.org/10.2147/bctt.s407181
Autor:
Lu Zhao, Jing Zhang, Na Wang, Dou Zhang, Ziwei Wang, Yongchao Yu, Qingyun Mei, Dongying Liao, Yingjie Jia, Fanming Kong
Publikováno v:
Anti-Cancer Drugs; Oct2023, Vol. 34 Issue 9, p978-984, 7p
Publikováno v:
OncoTargets and therapy
Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50336a4c7ac1003455f5ad9a10e908f1
https://doi.org/10.2147/ott.s317434
https://doi.org/10.2147/ott.s317434
Publikováno v:
Breast cancer (Dove Medical Press). 14
Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f5597e8069e16acadf730b7810e0067
https://pubmed.ncbi.nlm.nih.gov/36532256
https://pubmed.ncbi.nlm.nih.gov/36532256
Publikováno v:
TMR Cancer. 4:13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42e9e636384eb02eee1320cd424c5307
https://doi.org/10.53388/tmrc201800103
https://doi.org/10.53388/tmrc201800103